Kushan Radadia, MD
Urology · Roswell, GANPI 1275949992
Payments from drug & device makers
Across 175 payments — averaging $35.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Boston Scientific$975
- Endo Pharmaceuticals Inc.$511
- Medtronic$462
- Verathon Inc.$375
- Astellas Pharma US Inc$321
- plus $3K from 32 others
What the payments were for
- Consulting fees$3756%
- Speaking & faculty fees$5018%
- Travel & lodging$4097%
- Food & beverage$4,88879%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 10 | $1,002 |
| Boston Scientific | 19 | $975 |
| Endo Pharmaceuticals Inc. | 18 | $511 |
| Medtronic | 9 | $462 |
| Verathon Inc. | 1 | $375 |
| Astellas Pharma US Inc | 17 | $321 |
| Dendreon Pharmaceuticals LLC | 6 | $271 |
| Sumitomo Pharma America, Inc. | 9 | $226 |
| Tolmar, Inc. | 11 | $217 |
| Convatec Inc. | 5 | $193 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $171 |
| Coloplast | 5 | $171 |
| Antares Pharma, Inc. | 8 | $137 |
| Endo USA, Inc. | 5 | $122 |
| Myriad Genetic Laboratories, Inc. | 6 | $120 |
| Pfizer | 6 | $117 |
| Dentsply IH AB | 5 | $99 |
| Tempus AI, Inc | 3 | $82 |
| Urogen Pharma, Inc. | 2 | $68 |
| Cook Medical LLC | 1 | $67 |
| AbbVie | 2 | $61 |
| Procept Biorobotics Corporation | 2 | $57 |
| Olympus America Inc. | 3 | $44 |
| Tolmar Pharmaceuticals, Inc. | 2 | $42 |
| Halozyme Inc | 2 | $38 |
| Urovant Sciences Inc | 2 | $34 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Novartis | 1 | $20 |
| Bayer | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $16 |
| Accord Healthcare, Inc. | 1 | $16 |
| BD | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$479
- ERECTILE DYSFUNCTION$470
- NPD Clinical Study$375
- INTERSTIM$308
- PROVENGE$146
- UroLift System$116
- AMS$114
- XIAFLEX$113
How this compares
$6,199 in reported general payments places this provider in the 60th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 75 | $49,571 |
| GemtesaVibegron | 50 | $39,636 |
| Mirabegron ErMirabegron | 15 | $6,651 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 259 | $3,527 |
| Tamsulosin Hcl | 282 | $2,774 |
| Methenamine Hippurate | 28 | $1,930 |
| Silodosin | 18 | $1,185 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 74 | $964 |
| Testosterone Cypionate | 19 | $938 |
| Finasteride | 53 | $454 |
| Dutasteride | 18 | $397 |
| Cefdinir | 24 | $226 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 101 | $180 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $77 |
| Ciprofloxacin Hcl | 20 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $321 | $49,57175 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $226 | $39,63650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 369 urology providers in Georgia.
Other urology in Roswell
- Vahan KassabianRoswell$3M
- Lewis KritemanRoswell$864K
- Scott MillerRoswell$85K
- Akash KapadiaRoswell$79K
- Herman BaggaRoswell$67K
- Sophia GoodridgeRoswell$18K
- Daniel BelewRoswell$16K
- Viraj MasterAtlanta$2M
- Vikram NarayanAtlanta$1.1M
- Daniel CanterDecatur$611K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.